| Document |
Document Title |
|
WO/2017/038873A1 |
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...
|
|
WO/2017/031156A1 |
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...
|
|
WO/2017/023907A1 |
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...
|
|
WO/2017/017036A1 |
The present invention relates to ureaurethanes of the following formula (1) in which at least one of the R1 or R2 radicals is a mono- or polyunsaturated, branched or unbranched alkenyl or alkynyl radical having 12 to 24 carbon atoms, n i...
|
|
WO/2017/016523A1 |
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical co...
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2016/210414A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2016/207726A1 |
The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/153354A9 |
Disclosed is a method for the integrated production of two different urea products. One is an aqueous urea solution suitable for use in NOx abatement (generally indicated as Diesel Exhaust Fluid – DEF). The other is a solution used as ...
|
|
WO/2016/172425A1 |
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)
|
|
WO/2016/168769A1 |
Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain TI...
|
|
WO/2016/161286A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2016/159336A1 |
The present invention is a urea production method characterized by comprising a first concentration step that concentrates an aqueous urea solution, a granulating step that produces solid urea from a concentrated aqueous urea solution ge...
|
|
WO/2016/156015A1 |
Process and respective reactor for urea or melamine synthesis, comprising sonication treatment of at least part of a reaction liquid mass or two-phase mixture contained inside said reactor.
|
|
WO/2016/149099A1 |
The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
|
|
WO/2016/127085A1 |
Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such ...
|
|
WO/2016/114670A1 |
The invention pertains to the synthesis of carbamate and urea compounds. In particular the invention is directed to the synthesis of carbamate and urea compounds which may be used in the production of compounds that are used to stabilize...
|
|
WO/2016/101885A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/093562A1 |
The present invention relates to an ionic catalyst comprising a nitrogen-containing organic cation chemically immobilized to a polymer resin carrier and an anion thereof, and a method for selectively preparing N,N'-substituted urea by re...
|
|
WO/2016/071347A1 |
The invention relates to novel carbodiimides comprising terminal urea and/or urethane groups of formula (I), in which R can be identical or different and is selected from the group of -NHCONHRI-, -NHCONR'RII- and -NHCOORIII- groups, wher...
|
|
WO/2016/063990A1 |
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...
|
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/052953A1 |
The present specification relates to a (meth)acrylate compound, and a copolymer and a homopolymer comprising a repeating unit derived from the compound.
|
|
WO/2016/052592A1 |
This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulae (1)-(3).
|
|
WO/2016/049774A1 |
Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the ...
|
|
WO/2016/049518A1 |
A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)ph
enyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR-101") suitable for oral dosing, and to compositions, methods and kits relating ther...
|
|
WO/2016/047356A1 |
The present invention relates to a process for producing a high-purity aqueous urea solution while utilizing a urea production process at least including a urea synthesis step in which urea is synthesized from feed materials to produce a...
|
|
WO/2016/049282A1 |
The invention relates to a compound prepared by (i) reacting (a) at least one compound selected from diisocyanate, polyisocyanate, or mixture thereof; (b) at least one isocyanate-reactive compound selected from a fluorinated alcohol; a c...
|
|
WO/2016/035328A1 |
Provided are: a dispersant which has excellent solubility in a solvent, excellent adhering power to a colorant and excellent colorant dispersibility, while being reduced in self-coloring; a compound and a polymerizable compound for prepa...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/030329A1 |
Novel efficient, time-saving and reliable radiofluorination procedures for the production of 18F-labelled active esters via nucleophilic substitution of the corresponding onium precursors with 18F- are described. The active ester includi...
|
|
WO/2016/016178A1 |
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
|
|
WO/2016/013633A1 |
A compound represented by formula (I) or a salt thereof has an excellent noxious organism control activity, particularly an excellent miticidal activity and/or an excellent insecticidal activity, is highly safe, and can be synthesized in...
|
|
WO/2016/010432A1 |
Disclosed is a process for the preparation of a urea product suitable for being diluted with water so as to form an aqueous urea comprising solution for use in a unit for the reduction of NOx in combustion engine exhaust gases, also know...
|
|
WO/2015/188060A1 |
Fluorosulfonyl-substituted sEH inhibitors are compounds represented by Formula (I): wherein R1 is selected from the group consisting of alkyl, heteroalkyi, C5-C12 cycloalkyi, C5-C12 cycloalkylalkyi, C5-C12 cycloalkylheteroalkyi, arylalky...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/176135A1 |
The present invention relates to new omega-3 fatty acid analogues and to their use in cancer therapy, including anti-metastatic therapy.
|
|
WO/2015/165352A1 |
The present invention provides a compound with a structure represented by general formula I or a pharmaceutically acceptable salt thereof, a preparation method for the compound or the salt, and a use of the compound or the pharmaceutical...
|
|
WO/2015/158792A1 |
The invention relates to rheology control agents comprising at least one active substance of general formula (I) and at least one active substance of general formula RB4OOC-NH-RB3-NH-CO-NRB2-(CH2)x-RB1-(CH2)x-RB2-CO-NH-RB3-NH-
COORB4, to...
|
|
WO/2015/158794A1 |
The invention relates to a urea preparation containing (A) 5 to 75 wt.% of one or more urea components which have a molecular weight of at least 350 g/mol and contain at least one urea group; (B) 15 to 95 wt.%, preferably 30 to 80 wt.%, ...
|
|
WO/2015/134839A1 |
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula (I): or pharmaceutically acceptable...
|
|
WO/2015/126150A1 |
The present application relates to a t-butyl ketone binaphthol derivative and a method for manufacturing same, the t-butyl ketone binaphthol derivative being a high-efficiency chiral-extracting agent which has very high chiral selectivit...
|
|
WO/2015/109666A1 |
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...
|
|
WO/2015/100252A1 |
Felbamate deuterated at the 2 position, compositions containing the same, and methods of making and using thereof are described herein. Substitution of the hydrogen at the 2 position with deuterium should prevent or reduce formation of t...
|
|
WO/2015/092807A1 |
The present invention provides a novel process for preparing Alogliptin free base and its benzoate salt which comprises insitu condensation process to produce protected Alogliptin by reacting 6-chloro-3-methylpyrimidine-2, 4(1H, 3H)-dion...
|
|
WO/2015/089962A1 |
Provided is a method for continuously preparing biuret polyisocyanate, comprising: a mixed solution of a diisocyanate and a catalyst with water vapour, in an aerosol form, are continuously reacted in a first reactor; the product obtained...
|
|
WO/2015/089271A1 |
A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R1 and R2 are each independently H; optionally substituted alkyl; optionally subs...
|
|
WO/2015/084299A1 |
Disclosed herein are gemini surfactants, and methods for making and using these gemini surfactants. These gemini surfactants may be incorporated in paints and coatings to provide hydrophilic and/or self-cleaning properties. Coatings and ...
|
|
WO/2015/080665A1 |
The invention relates to compounds of formula (I) or derivatives, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites or prodrugs thereof, in which ...
|
